 Arpita Desai, MD
|
| Title(s) | Assistant Professor, Medicine |
|---|
| School | School of Medicine |
|---|
| Address | 550 16th. Street
San Francisco CA 94158
|
|---|
| Phone | -- |
|---|
| vCard | Download vCard |
|---|
|
|
 Biography | State University of New York at Buffalo | Residency | 2015 | Internal Medicine | | University of Chicago | Fellowship | 2018 | Medical Oncology |
| SUNY at Buffalo | 2014 | | Dexter S. Levy Memorial Award | | SUNY at Buffalo | 2015 | | Thomas F. Frawley Research Fellowship Award | | ASCO | 2018 | | Conquer Cancer Foundation of ASCO/Frances A. Shepherd, MD, Endowed Merit Award | | IASLC | 2018 | | Young Investigator Award |
Overview Dr. Arpita Desai is an oncologist who specializes in the treatment of patients with genitourinary cancers, in particular kidney and prostate cancers.
Desai is interested in developing novel imaging and therapeutic strategies in renal cell cancer with the goal of improving outcomes by personalizing therapy. The scope of her most recent work has been related to incorporating functional and molecular imaging to personalize treatment in GU malignancies.
Desai completed her residency in internal medicine at the State University of New York where she also served as chief resident of internal medicine. She completed a fellowship in medical oncology at the University of Chicago. She is a member of the American Society of Clinical Oncology (ASCO) and American Association for Cancer Research (AACR).
ORNG Applications Bibliographic
Altmetrics Details
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media.
(Note that publications are often cited in additional ways that are not shown here.)
Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication.
Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication.
Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.)
Click a Field or Translation tag to filter the publications.
-
Treatment of advanced renal cell carcinoma patients with cabozantinib, an oral multityrosine kinase inhibitor of MET, AXL and VEGF receptors. Future Oncol. 2019 Jul; 15(20):2337-2348.
Desai A, Small EJ. PMID: 31184937.
View in: PubMed Mentions: 3 Fields: Translation: HumansCells
This graph shows the total number of publications by year. To see the data as text, click here.
This graph shows the total number of publications by year. To return to the graph, click here.
This graph shows the number and percent of publications by field.
Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications.
Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written.
To see the data as text, click here.
This graph shows the number and percent of publications by field.
Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications.
Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written.
To see the data as text, click here.
newest
oldest
line numbers
double spacing
all authors
publication IDs
|
Derived automatically from this person's publications.
_
People in Profiles who have published with this person.
_
People who share similar concepts with this person.
_
Search Department
_
|